N-<2-Fluor-aethyl>-cyclohexylamin | 673-38-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-<2-Fluor-aethyl>-cyclohexylamin
• 英文别名: N-2-Fluorethylcyclohexylamin；N-(2-fluoroethyl)cyclohexanamine
• CAS: 673-38-1
• 化学式: C₈H₁₆FN
• 分子量: 145.22
• InChiKey: ZKDLVKWHIHOHSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF<br/>[FR] 6-(HÉTÉROARYLE À 5 CHAÎNONS)ISOQUINOLIN-3-YL CARBOXAMIDES, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：SAMUMED LLC

  公开号：WO2019079626A1

  公开（公告）日：2019-04-25

  Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
• [EN] PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES.<br/>[FR] COMPOSÉS DE PYRIDO-PYRIMIDINONE ET DE PTÉRIDINONE UTILISÉS EN TANT QU'INHIBITEURS DE L'ENZYME NÉCESSITANT L'INOSITOL I (IRE I ALPHA) À ACTIVITÉ ENDORIBONUCLÉASE POUR LE TRAITEMENT DE MALADIES CANCÉREUSES
  申请人：GENENTECH INC

  公开号：WO2020142612A1

  公开（公告）日：2020-07-09

  Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods treating cancer, alone and in combination with other therapeutic agents.